S2 vs Pathway Expression

	S2	1	0	IC(Δ)	P-val	FDR

Pathway	IC(Δ)	P-val	FDR
TAUBE_EMT	0.664(0.015)	2.62e-06	5.46e-05
SMID_BREAST_CANCER_NORMAL_LIKE	0.660(0.017)	2.62e-06	5.46e-05
GROGER_EMT	0.656(0.017)	2.62e-06	5.46e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE	0.649(0.015)	2.62e-06	5.46e-05
ONDER_CDH1_TARGETS_2	0.636(0.018)	2.62e-06	5.46e-05
COLDREN_GEFITINIB_RESISTANCE	0.634(0.018)	2.62e-06	5.46e-05
HEIDENBLAD_AMPLICON_12P11_12	0.624(0.018)	2.62e-06	5.46e-05
GU_PDEF_TARGETS	0.617(0.019)	2.62e-06	5.46e-05
HEIDENBLAD_AMPLICON_12P11_12_UP	0.615(0.019)	2.62e-06	5.46e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL	0.615(0.017)	2.62e-06	5.46e-05
LIM_MAMMARY_STEM_CELL	0.614(0.018)	2.62e-06	5.46e-05
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2	0.600(0.022)	2.62e-06	5.46e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN	0.591(0.019)	2.62e-06	5.46e-05
KRAS.Breast_HMLE.Weeks	0.591(0.019)	2.62e-06	5.46e-05
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL	0.584(0.019)	2.62e-06	5.46e-05
LABBE_TGFB1_TARGETS	0.581(0.021)	2.62e-06	5.46e-05
ROY_WOUND_BLOOD_VESSEL	0.569(0.022)	2.62e-06	5.46e-05
COLDREN_GEFITINIB_RESISTANCE_UP	0.568(0.020)	2.62e-06	5.46e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	0.564(0.022)	2.62e-06	5.46e-05
HINATA_NFKB_TARGETS_KERATINOCYTE	0.562(0.019)	2.62e-06	5.46e-05
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES	-0.606(0.019)	2.62e-06	5.73e-05
LINDGREN_BLADDER_CANCER_CLUSTER_2A	-0.609(0.019)	2.62e-06	5.73e-05
LIM_MAMMARY_STEM_CELL_DN	-0.611(0.022)	2.62e-06	5.73e-05
TAUBE_EMT_DN	-0.611(0.020)	2.62e-06	5.73e-05
LANDIS_BREAST_CANCER_PROGRESSION_UP	-0.612(0.020)	2.62e-06	5.73e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN	-0.615(0.019)	2.62e-06	5.73e-05
NADELLA_PRKAR1A_TARGETS	-0.617(0.018)	2.62e-06	5.73e-05
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP	-0.638(0.017)	2.62e-06	5.73e-05
GROGER_EMT_DN	-0.642(0.019)	2.62e-06	5.73e-05
AIGNER_ZEB1_TARGETS	-0.642(0.021)	2.62e-06	5.73e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	-0.650(0.017)	2.62e-06	5.73e-05
COLDREN_GEFITINIB_RESISTANCE_DN	-0.651(0.017)	2.62e-06	5.73e-05
BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP	-0.652(0.017)	2.62e-06	5.73e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL	-0.656(0.019)	2.62e-06	5.73e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	-0.658(0.019)	2.62e-06	5.73e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL	-0.658(0.016)	2.62e-06	5.73e-05
LOPEZ_EPITHELIOID_MESOTHELIOMA	-0.659(0.017)	2.62e-06	5.73e-05
SMID_BREAST_CANCER_NORMAL_LIKE_DN	-0.665(0.019)	2.62e-06	5.73e-05
LANDIS_BREAST_CANCER_PROGRESSION	-0.666(0.018)	2.62e-06	5.73e-05
LANDIS_ERBB2_BREAST_TUMORS_324	-0.677(0.015)	2.62e-06	5.73e-05